GNMLF (Genomma Lab InternacionalB de CV) LT-Debt-to-Total-Asset : 0.21 (As of Dec. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Genomma Lab InternacionalB de CV LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Genomma Lab InternacionalB de CV's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.21.

Genomma Lab InternacionalB de CV's long-term debt to total assets ratio increased from Dec. 2023 (0.20) to Dec. 2024 (0.21). It may suggest that Genomma Lab InternacionalB de CV is progressively becoming more dependent on debt to grow their business.

Genomma Lab InternacionalB de CV LT-Debt-to-Total-Asset Historical Data

The historical data trend for Genomma Lab InternacionalB de CV's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genomma Lab InternacionalB de CV LT-Debt-to-Total-Asset Chart

Genomma Lab InternacionalB de CV Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.21

0.18

0.07

0.20

0.21

Genomma Lab InternacionalB de CV Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.20	0.19	0.22	0.22	0.21

Genomma Lab InternacionalB de CV LT-Debt-to-Total-Asset Calculation

Genomma Lab InternacionalB de CV's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	242.85	/	1154.721
	=	0.21

Genomma Lab InternacionalB de CV's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	242.85	/	1154.721
	=	0.21

Genomma Lab InternacionalB de CV (OTCPK:GNMLF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Genomma Lab InternacionalB de CV LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Genomma Lab InternacionalB de CV's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Genomma Lab InternacionalB de CV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Genomma Lab Internacional SAB de CV (OTCPK:GNMLF) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

LABB:Mexico GEKA:Germany

Address

Avenida Antonio Dovali Jaime, Number 70, Tower C, Floor 2, Office A. Colonia Santa Fe, Del. Alvaro Obregon, Mexico, MEX, MEX, CP 01210

Website

https://www.genommalab.com

Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.